DOJ Seeks Strategic Pause in State-Led Mifepristone Litigation Amid FDA Review

The Department of Justice’s recent filing in a Missouri federal court marks a significant pivot in the federal government’s approach to medication abortion litigation. By formally requesting a stay in proceedings, the DOJ is attempting to shield the Food and Drug Administration (FDA) from immediate judicial mandates while the agency conducts what it describes as a comprehensive internal review of mifepristone’s safety and distribution protocols. This maneuver, which mirrors a similar request made in Louisiana earlier this year, suggests a strategic effort to centralize the regulatory narrative within the executive branch rather than allowing it to be dictated by a patchwork of state-led lawsuits.

The Missouri litigation, spearheaded by Attorney General Catherine Hanaway and joined by attorneys general from Kansas and Idaho, represents a direct assault on the FDA’s modern regulatory framework for medication abortion. The plaintiffs are seeking to roll back the gestational age limit for mifepristone from ten weeks to seven and are demanding a total prohibition on telehealth prescriptions and mail-order delivery. The states argue that the current protocols lack sufficient physician oversight, a position that challenges the FDA’s long-standing clinical assessments. By intervening now, the DOJ is effectively arguing that the court should defer to the agency’s expertise while it re-evaluates the drug, a move that could potentially stall a final ruling until after the upcoming midterm elections.

“

While federal attorneys plead for a stay in Missouri, Senator Josh Hawley has introduced a bill in the Senate that would bypass the courts and the FDA entirely by implementing a nationwide ban on mifepristone.

From a regulatory and legal technology perspective, this development highlights the escalating tension between state-level enforcement and federal preemption. The DOJ’s legal team argued in their filing that the various ongoing lawsuits create a state of regulatory confusion that interferes with the FDA’s ability to perform its duties. This reliance on the doctrine of administrative exhaustion—the idea that the agency should be allowed to finish its internal processes before courts intervene—is a standard defense in administrative law. However, the timing of these requests has led many observers to conclude that the administration is seeking to avoid the political volatility of a major court ruling during an election cycle, preferring the slower, more controlled pace of federal rulemaking.